Hong Kong stock surged again, Fosun Pharma (02196.HK) rose more than 4%, the company obtained exclusive licensing rights to NeuCure's Alzheimer's disease innovative drug AR1001.
According to the Securities Times app, Fosun Pharma (02196.HK) has risen by over 4% again, as of the press release, up 4.3%, to HK$20.15, with a turnover of HK$2.01 billion.
Latest
